Table 8.6a

Immunosuppression Use for Induction, 1993 to 2002

Recipients with Kidney-Pancreas Transplants

	Year of Transplant
	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants	661	748	919	860	853	972	941	914	891	905
Tx With Immunosuppression Info	638	714	912	845	842	957	916	881	870	881
No Induction Drugs Recorded	72.4%	53.2%	42.4%	27.0%	31.8%	38.9%	37.9%	30.5%	25.6%	26.2%
Drugs	0.0%	0.0%	0.0%	0.0%	-	-	-	-	-	-
ALG
ATG	1.1%	0.1%	1.9%	25.6%	29.5%	11.2%	5.6%	3.0%	2.3%	2.6%
NRATG/NRATS	-	0.1%	0.4%	0.8%	0.8%	0.4%	0.2%	-	-	-
OKT3	26.6%	46.8%	56.0%	47.9%	39.4%	26.0%	14.0%	7.4%	3.2%	0.9%
Thymoglobulin	-	-	-	0.1%	-	0.1%	4.6%	17.7%	28.2%	36.5%
Zenapax	-	0.1%	0.3%	0.1%	0.2%	18.8%	24.7%	19.6%	19.7%	16.0%
Simulect	0.0%	0.1%	0.3%	0.1%	0.2%	7.1%	16.4%	26.3%	30.2%	25.2%

Source: OPTN/SRTR Data as of August 1, 2003.

(-) = Drug not used anytime during the year.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.